Ocrevus appears to be a safe and effective treatment for children and adolescents with MS, according to real-world data from ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

Researchers still don’t fully understand the cause of multiple sclerosis or why the rate of progression is so difficult to ...

In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral ...

The initial proceeds to Immunic from the offering were approximately $65 million, before deducting underwriting discounts and commissions and offering expenses. The Company may receive up to an ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small ...

Roche Holdings AG (OTC:RHHBY) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with ...

Early diagnosis and treatment aim to minimise the impact of multiple sclerosis on their daily lives and extend their ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

Roche has revealed new results from a phase 2 trial of its oral BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS) that suggest it can prevent progression of the disease for nearly two ...